Research Reports | Market Assessment
April 2016

Psoriasis | Unmet Need | US/EU | 2016

 

Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial potential. Significant opportunities exist for emerging therapies to differentiate themselves by addressing important unmet needs such as improved efficacy outcomes on more-stringent measures, a better risk-benefit profile, more-convenient delivery formulation, and an oral drug with efficacy comparable to that of the biologics.

 

 

 

 

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports